ATE106748T1 - Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum. - Google Patents

Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Info

Publication number
ATE106748T1
ATE106748T1 AT90915992T AT90915992T ATE106748T1 AT E106748 T1 ATE106748 T1 AT E106748T1 AT 90915992 T AT90915992 T AT 90915992T AT 90915992 T AT90915992 T AT 90915992T AT E106748 T1 ATE106748 T1 AT E106748T1
Authority
AT
Austria
Prior art keywords
hiv
infections
vaccines
protection against
immunotherapeutic
Prior art date
Application number
AT90915992T
Other languages
German (de)
English (en)
Inventor
Ursula Dietrich
Michalina Adamski
Briesen Hagen Von
Herbert Kuehnel
Helga Ruebsamen-Waigmann
Original Assignee
Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6391493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE106748(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemotherapeutisches Forschungsinstitut Georg Speyer Haus filed Critical Chemotherapeutisches Forschungsinstitut Georg Speyer Haus
Application granted granted Critical
Publication of ATE106748T1 publication Critical patent/ATE106748T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT90915992T 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum. ATE106748T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3934366A DE3934366A1 (de) 1989-10-14 1989-10-14 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum

Publications (1)

Publication Number Publication Date
ATE106748T1 true ATE106748T1 (de) 1994-06-15

Family

ID=6391493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90915992T ATE106748T1 (de) 1989-10-14 1990-10-12 Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.

Country Status (8)

Country Link
US (1) US5861243A (enExample)
EP (1) EP0495896B1 (enExample)
JP (1) JP3152433B2 (enExample)
AT (1) ATE106748T1 (enExample)
DE (2) DE3934366A1 (enExample)
DK (1) DK0495896T3 (enExample)
ES (1) ES2055922T3 (enExample)
WO (1) WO1991005567A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98845A0 (en) * 1990-07-19 1992-07-15 Merck & Co Inc Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties,their preparation and pharmaceutical compositions containing them
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
ATE374253T1 (de) * 1994-10-20 2007-10-15 Pasteur Institut Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o
US6124262A (en) * 1995-03-17 2000-09-26 The Regents Of The University Of California Compositions and methods for reducing adhesiveness of defective red blood cells
US6426412B1 (en) * 1995-12-20 2002-07-30 Subsidiary No. 3, Inc. Nucleic acids encoding human immunodeficiency virus type 1 genetic suppressor elements
ATE296898T1 (de) * 1997-03-20 2005-06-15 Affymetrix Inc Iterative resequenzierung
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2000029561A2 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
NZ515322A (en) * 1999-05-13 2004-03-26 Wyeth Corp Adjuvant combination formulations
AU784679B2 (en) * 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
IL155690A0 (en) * 2000-11-10 2003-11-23 Wyeth Corp Adjuvant combination formulations
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
JP2008535783A (ja) 2005-02-15 2008-09-04 サイモン・エル・エル・シー Ｈｉｖ−１の増殖を弱めるための方法および組成物
US20100275278A1 (en) * 2006-02-03 2010-10-28 Karp Nelson M Animal model for hiv induced disease
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
CN115124628B (zh) * 2021-03-27 2023-03-31 中国科学院昆明植物研究所 一种白及多糖及其制备方法和应用、包含所述白及多糖的免疫佐剂和纳米疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2948823B2 (ja) * 1987-01-16 1999-09-13 アンステイテユ・パストウール ヒト免疫不全レトロウィルス（ｈｉｖ）関連抗原性ペプチド、そのウィルス感染の検出及びワクチンへの使用
ATE241014T2 (de) * 1988-06-14 2003-06-15 Qiagen Gmbh Hiv-2 varianten

Also Published As

Publication number Publication date
DK0495896T3 (da) 1994-10-10
JPH05505389A (ja) 1993-08-12
EP0495896A1 (de) 1992-07-29
DE3934366A1 (de) 1991-04-18
DE59006080D1 (de) 1994-07-14
EP0495896B1 (de) 1994-06-08
WO1991005567A1 (de) 1991-05-02
ES2055922T3 (es) 1994-09-01
US5861243A (en) 1999-01-19
JP3152433B2 (ja) 2001-04-03
DE3934366C2 (enExample) 1991-11-07

Similar Documents

Publication Publication Date Title
ATE106748T1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
FI903154A0 (fi) Kimeriska glykoproteiner innehaollande immunogeniska segment av glykoproteiner av maenniskans respiratory syncytial-virus.
DE3751751D1 (de) Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
DK0440777T3 (da) Neurotrofisk faktor stammende fra hjernen
ATE172642T1 (de) Impfstoffe und verfahren zu ihrer herstellung
DE3784907D1 (de) Oligosaccharide, immunogene und impstoffe und verfahren zur herstellung dieser oligosaccharide, immunogene und impstoffe.
DE69936337T2 (de) Verfahren zur entwicklung von einem hiv impfstoff
EP0342860A3 (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
GR3022248T3 (en) Oligonucleotide sequences for amplification of type HIV-2 and SIV retroviruses genomes and their application to in-vitro diagnostic of infections caused by these viruses
KR890700030A (ko) 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법
ATE82985T1 (de) Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
ATE187496T1 (de) Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
ATE16454T1 (de) Influenzavirus-vaccine, verfahren zu ihrer herstellung und verfahren zur vermehrung von influenzaviren.
EP0432220A4 (en) Vaccines and diagnostic assays for haemophilus influenzae
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
CA2072095A1 (en) Outer membrane protein p1 and peptides of haemophilus influenzae type b
HUT54412A (en) Process for producing retrovirus proteaze, reverze transkriptaze and endonucleaze enzymes
PT87940A (pt) Processo para a preparacao de dna do virus papillom humano tipo 41 e de proteinas por ele codificadas
US4931393A (en) Non-infectious mutant clone of HIV
Doherty The keys to cell-mediated immunity
EP0218431A3 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
Ottesen et al. Correlation between HLA-A, B, C expression on human urothelial cell lines and transformation grade in vitro
Oren et al. Biological and molecular properties of p53
TH23870A (th) วัคซีนและวิธีสำหรับการเตรียม

Legal Events

Date Code Title Description
RZN Patent revoked